Vaxart (VXRT) Proxy filing summary

Executive summary

• Approaching critical operational and clinical milestones, including key vaccine program advancements.

• Strategic focus on oral vaccine programs for COVID-19, norovirus, and influenza, leveraging the VAAST platform.

• Decisive actions taken to strengthen financial position, including restoring funding, securing partnerships, and streamlining operations.

• Ended Q1 2026 with $61 million in cash, providing runway into Q2 2027.

• Forward-looking statements highlight expectations for clinical results, regulatory progress, and capital resources.

Voting matters and shareholder proposals

• Shareholders urged to vote “FOR” all 6 board nominees on the WHITE proxy card at the July 16, 2026 Annual Meeting.

• A small group of shareholders is seeking to replace current directors; board determined their nominees lack relevant experience.

• Only the latest valid proxy card counts; shareholders encouraged to discard materials from the opposing group.

Board of directors and corporate governance

• Board intentionally composed of directors with expertise in vaccine development, regulatory strategy, and commercialization.

• Recent addition of Dr. James B. Breitmeyer brings over 35 years of clinical and regulatory experience.

• All directors are shareholders, aligning their interests with those of other investors.

• Board refreshment and ongoing evaluation of director qualifications are emphasized.